<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">34924160</PMID><DateCompleted><Year>2022</Year><Month>01</Month><Day>17</Day></DateCompleted><DateRevised><Year>2022</Year><Month>01</Month><Day>17</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2530-0180</ISSN><JournalIssue CitedMedium="Internet"><Volume>68</Volume><Issue>10</Issue><PubDate><Year>2021</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Endocrinologia, diabetes y nutricion</Title><ISOAbbreviation>Endocrinol Diabetes Nutr (Engl Ed)</ISOAbbreviation></Journal><ArticleTitle>Status of diabetes control and knowledge about diabetes in patients.</ArticleTitle><Pagination><StartPage>716</StartPage><EndPage>727</EndPage><MedlinePgn>716-727</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.endien.2021.12.003</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S2530-0180(21)00164-5</ELocationID><Abstract><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">There are a number of studies in the literature which show that knowledge about the diabetes mellitus is related to socioeconomic status, education, duration of diabetes, age, sex, and family history. The above facts have prompted us to evaluate the status of knowledge of diabetes in our patients at the diabetic clinic Vivekananda Polyclinic and Institute of Medical Sciences (VPIMS), Lucknow, India. The main objective of this study is to evaluate the knowledge of diabetes among the suffering with people with type-2 diabetes mellitus and its correlation with diabetes control.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">The participants' knowledge about diabetes and their understanding about control and complications of diabetes were assessed by a standardized questionnaire. The data was collected at a single, routine visit of the patient to the diabetic clinic at VPIMS, Lucknow, India over a period of 1 year after detailed clinical examination and relevant investigations.</AbstractText><AbstractText Label="RESULT" NlmCategory="RESULTS">Only 50% of the patients know what diabetes is, 46% know it is a hereditary disease, 68.8% know about its symptoms, 50% have complete knowledge about complications, 45.2%, know simple treatments of diabetes. Among educated graduate and professional category majority of subjects (62.5%) had good level of knowledge about diabetes which was statistically significant (p&lt;0.001). Those having frequent/regular exercise, having higher education and shorter duration of diabetes had a better control over postprandial (PP) blood sugar as compared to those having occasional/no exercise and lower level of education (p&lt;0.05).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The findings indicate a greater need for behavioral change to control diabetes and its associated threats.</AbstractText><CopyrightInformation>Copyright &#xa9; 2021 SEEN and SED. Published by Elsevier Espa&#xf1;a, S.L.U. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sharma</LastName><ForeName>Praveen Kumar</ForeName><Initials>PK</Initials><AffiliationInfo><Affiliation>Balrampur Hospital, Lucknow 226016, India. Electronic address: Drpraveen72@yahoo.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rajpal</LastName><ForeName>Naresh</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Vivekanand Polyclinic, Nirala Nagar, Lucknow 226020, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Upadhyay</LastName><ForeName>Shushil</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Vivekanand Polyclinic, Nirala Nagar, Lucknow 226020, India; Saha Hospital, Sector D, LDA Colony, Kanpur Road, Lucknow 226012, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shaha</LastName><ForeName>Devashish</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Vivekanand Polyclinic, Nirala Nagar, Lucknow 226020, India; Hospital Nirala Nagar, Railway Crossing Road, Bans Mandi, Nirala Nagar, Lucknow 226020, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Deo</LastName><ForeName>Narendra</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Balrampur Hospital, Lucknow 226016, India.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Spain</Country><MedlineTA>Endocrinol Diabetes Nutr (Engl Ed)</MedlineTA><NlmUniqueID>101717565</NlmUniqueID><ISSNLinking>2530-0180</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001786">Blood Glucose</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001786" MajorTopicYN="N">Blood Glucose</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003924" MajorTopicYN="Y">Diabetes Mellitus, Type 2</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004522" MajorTopicYN="N">Educational Status</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011795" MajorTopicYN="N">Surveys and Questionnaires</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Conocimiento</Keyword><Keyword MajorTopicYN="N">Diabetes (type 2) mellitus</Keyword><Keyword MajorTopicYN="N">Diabetes mellitus (tipo 2)</Keyword><Keyword MajorTopicYN="N">Estratos socioecon&#xf3;micos</Keyword><Keyword MajorTopicYN="N">Knowledge</Keyword><Keyword MajorTopicYN="N">Pacientes</Keyword><Keyword MajorTopicYN="N">Patients</Keyword><Keyword MajorTopicYN="N">Pr&#xe1;cticas de cuidado personal</Keyword><Keyword MajorTopicYN="N">Self-care practices</Keyword><Keyword MajorTopicYN="N">Socioeconomic strata</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>8</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>12</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>12</Month><Day>20</Day><Hour>5</Hour><Minute>39</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>12</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>1</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34924160</ArticleId><ArticleId IdType="doi">10.1016/j.endien.2021.12.003</ArticleId><ArticleId IdType="pii">S2530-0180(21)00164-5</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">29099829</PMID><DateCompleted><Year>2019</Year><Month>01</Month><Day>31</Day></DateCompleted><DateRevised><Year>2022</Year><Month>12</Month><Day>07</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0016-3813</ISSN><JournalIssue CitedMedium="Print"><Volume>153</Volume><Issue>Supl. 2</Issue><PubDate><Year>2017</Year></PubDate></JournalIssue><Title>Gaceta medica de Mexico</Title><ISOAbbreviation>Gac Med Mex</ISOAbbreviation></Journal><ArticleTitle>[Sitaglitpin phosphate treatment in patients with reactive hypoglycemia secondary to dysinsulinism. Controlled, randomized, double-blind study].</ArticleTitle><Pagination><StartPage>S51</StartPage><EndPage>S59</EndPage><MedlinePgn>S51-S59</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.24875/GMM.M17000007</ELocationID><Abstract><AbstractText Label="OBJECTIVE">We evaluated the effect of sitagliptin in correction of symptomatic reactive hypoglycemia.</AbstractText><AbstractText Label="METHODS">Randomized, double blind, placebo-controlled clinical trial. Thirteen patients treated with sitagliptin and 15 with placebo, with mean age of 34.3 &#xb1; 10.6 years and body mass index of 24.6 &#xb1; 5.1 kg/m<sup>2</sup>, mostly women (n = 24, 85.7%), were evaluated.</AbstractText><AbstractText Label="RESULTS">Basal glycemia was similar in placebo versus sitagliptin (92.3 &#xb1; 18.9 vs. 93.4 &#xb1; 17.3 mg/dl; p = 0.41) as was median and interquartile range of insulin (15.2 [8.8-43.7] vs. 14.7 &#xb5;U/ml [7.0-39.0]; p = 0.44). Patients with sitagliptin recovered the first phase insulin secretion (FISP). This was related with higher glucose level at the end of the oral glucose tolerance test (79.5 [74.2-83.0] vs. 83.5 [81.2-89.7]; p = 0.003) with a similar insulin median level (13.0 [5.0-34.4] vs. 13.8 [4.8-30.6]; p = 0.32). Symptomatology was significantly lower under sitagliptin treatment (p &lt; 0.0001).</AbstractText><AbstractText Label="CONCLUSIONS">Sitagliptin improved FISP and reduced post-prandial symptomatology. These results suggest a novel therapeutic option for patients with reactive hypoglycemia related with FISP.</AbstractText><CopyrightInformation>Copyright: &#xa9; 2017 Secretar&#xcd;a de Salud</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Cuevas-Ramos</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Departamento de Endocrinolog&#xed;a y Metabolismo, Instituto Nacional de Ciencias M&#xe9;dicas y Nutrici&#xf3;n Salvador Zubir&#xe1;n, Ciudad de M&#xe9;xico, M&#xe9;xico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Almeda-Vald&#xe9;s</LastName><ForeName>Paloma</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Departamento de Endocrinolog&#xed;a y Metabolismo, Instituto Nacional de Ciencias M&#xe9;dicas y Nutrici&#xf3;n Salvador Zubir&#xe1;n, Ciudad de M&#xe9;xico, M&#xe9;xico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meza-Arana</LastName><ForeName>Clara E</ForeName><Initials>CE</Initials><AffiliationInfo><Affiliation>Departamento de Endocrinolog&#xed;a y Metabolismo, Instituto Nacional de Ciencias M&#xe9;dicas y Nutrici&#xf3;n Salvador Zubir&#xe1;n, Ciudad de M&#xe9;xico, M&#xe9;xico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brito-C&#xf3;rdova</LastName><ForeName>Griselda</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Departamento de Endocrinolog&#xed;a y Metabolismo, Instituto Nacional de Ciencias M&#xe9;dicas y Nutrici&#xf3;n Salvador Zubir&#xe1;n, Ciudad de M&#xe9;xico, M&#xe9;xico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ruiz-G&#xf3;mez</LastName><ForeName>Doris Georgina</ForeName><Initials>DG</Initials><AffiliationInfo><Affiliation>Departamento de Endocrinolog&#xed;a y Metabolismo, Instituto Nacional de Ciencias M&#xe9;dicas y Nutrici&#xf3;n Salvador Zubir&#xe1;n, Ciudad de M&#xe9;xico, M&#xe9;xico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Razo</LastName><ForeName>Christian</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Departamento de Endocrinolog&#xed;a y Metabolismo, Instituto Nacional de Ciencias M&#xe9;dicas y Nutrici&#xf3;n Salvador Zubir&#xe1;n, Ciudad de M&#xe9;xico, M&#xe9;xico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>G&#xf3;mez-P&#xe9;rez</LastName><ForeName>Francisco J</ForeName><Initials>FJ</Initials><AffiliationInfo><Affiliation>Departamento de Endocrinolog&#xed;a y Metabolismo, Instituto Nacional de Ciencias M&#xe9;dicas y Nutrici&#xf3;n Salvador Zubir&#xe1;n, Ciudad de M&#xe9;xico, M&#xe9;xico.</Affiliation></AffiliationInfo></Author></AuthorList><Language>spa</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType></PublicationTypeList><VernacularTitle>Tratamiento con fosfato de sitagliptina en pacientes con hipoglucemia reactiva secundaria a disinsulinismo. Estudio controlado, aleatorizado y doble ciego.</VernacularTitle></Article><MedlineJournalInfo><Country>Mexico</Country><MedlineTA>Gac Med Mex</MedlineTA><NlmUniqueID>0010333</NlmUniqueID><ISSNLinking>0016-3813</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001786">Blood Glucose</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D006442">Glycated Hemoglobin A</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007004">Hypoglycemic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007328">Insulin</NameOfSubstance></Chemical><Chemical><RegistryNumber>TS63EW8X6F</RegistryNumber><NameOfSubstance UI="D000068900">Sitagliptin Phosphate</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001786" MajorTopicYN="N">Blood Glucose</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015992" MajorTopicYN="N">Body Mass Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003924" MajorTopicYN="N">Diabetes Mellitus, Type 2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018149" MajorTopicYN="N">Glucose Intolerance</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006442" MajorTopicYN="N">Glycated Hemoglobin</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007003" MajorTopicYN="N">Hypoglycemia</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007004" MajorTopicYN="N">Hypoglycemic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007328" MajorTopicYN="N">Insulin</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000068900" MajorTopicYN="N">Sitagliptin Phosphate</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Diabetes</Keyword><Keyword MajorTopicYN="N">Glucose</Keyword><Keyword MajorTopicYN="N">Insulin</Keyword><Keyword MajorTopicYN="N">Reactive hypoglycemia</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>11</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>11</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>2</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">29099829</ArticleId><ArticleId IdType="doi">10.24875/GMM.M17000007</ArticleId><ArticleId IdType="pii">j153/Supl.2/S51</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">25795941</PMID><DateCompleted><Year>2016</Year><Month>12</Month><Day>13</Day></DateCompleted><DateRevised><Year>2016</Year><Month>12</Month><Day>30</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1699-5198</ISSN><JournalIssue CitedMedium="Internet"><Volume>31</Volume><Issue>4</Issue><PubDate><Year>2015</Year><Month>Apr</Month><Day>01</Day></PubDate></JournalIssue><Title>Nutricion hospitalaria</Title><ISOAbbreviation>Nutr Hosp</ISOAbbreviation></Journal><ArticleTitle>[Figures performance of glycemia in type 2 diabetic patients with intake of two breakfast with the same amount of carbohydrates].</ArticleTitle><Pagination><StartPage>1558</StartPage><EndPage>1565</EndPage><MedlinePgn>1558-65</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3305/nh.2015.31.4.8304</ELocationID><Abstract><AbstractText Label="UNLABELLED">Simple Carbohydrates (CHO) in the cardiometabolic risk, lead to the increase of blood glucose and to insulin levels and in the long-term to Diabetes Mellitus type 2( T2DM).</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To determine the behavior of glycemia figures in T2DM patients with intake of two breakfasts.</AbstractText><AbstractText Label="METHODOLOGY" NlmCategory="METHODS">We evaluated by anthropometry, biochemical and clinical 14 patients with DM2 who were administered 2 breakfasts at different times with 50g of CHO represented in sweet biscuit and white bread.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">alteration was evident in 92.8% of low-density cholesterol (Ldlc), Total Cholesterol (TC) and high density cholesterol (Hdlc) in 50% and triacylglycerol (TG) in 35.7%. The behavior of blood sugar for breakfast with a sweet biscuit did not show significant difference in the preprandial and postprandial figure at the 2and 3 hours (p = 0.051 and 0.054 respectively) blood glucose 2 hours to 3 hours showed significance (p = 0.012). At breakfast with white bread the preprandial and postprandial blood glucose increased at the 2 hours (p = 0.006), while at the 3 hours, the number reported between 2 and 3 hours did not show significantly difference(p = 0.114 and 0.051 respectively). When comparing each of glycemia of the breakfasts in the preprandial periods at 2 and 3 hours, no statistically significant differences were found (p&gt; 0.05).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">isocaloric amounts of carbohydrates of two eaten breakfasts on different days acted similarly in glycemia figures. Breakfast with cookie favor the diabetic population because of the ingredients used on its preparation given their dyslipidemia.</AbstractText><CopyrightInformation>Copyright AULA MEDICA EDICIONES 2014. Published by AULA MEDICA. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rueda P&#xe1;ez</LastName><ForeName>Elsy Victoria</ForeName><Initials>EV</Initials><AffiliationInfo><Affiliation>Magister en Ciencias de la Nutrici&#xf3;n con menci&#xf3;n en Nutrici&#xf3;n Cl&#xed;nica. Universidad de Pamplona. Grupo de Investigaci&#xf3;n en Salud Humana. Departamento de Nutrici&#xf3;n y Diet&#xe9;tica.. elsyrueda@unipamplona.edu.co.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maldonado Obando</LastName><ForeName>Yohanna del Carmen</ForeName><Initials>Ydel C</Initials><AffiliationInfo><Affiliation>Especialista en Protecci&#xf3;n de Alimentos. Universidad de Pamplona. Grupo de Investigaci&#xf3;n en Recursos Naturales. Departamento de Alimentos.. elsyrueda@unipamplona.edu.co.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Caballero P&#xe9;rez</LastName><ForeName>Luz Alba</ForeName><Initials>LA</Initials><AffiliationInfo><Affiliation>Magister en Ciencia de los Alimentos. Universidad de Pamplona. Grupo de Investigaci&#xf3;n en Recursos Naturales. Departamento de Alimentos. Colombia.. elsyrueda@unipamplona.edu.co.</Affiliation></AffiliationInfo></Author></AuthorList><Language>spa</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>Comportamiento de cifras de glucemia en pacientes diab&#xe9;ticos tipo 2 con la ingesta de dos desayunos con igual cantidad de carbohidratos.</VernacularTitle><ArticleDate DateType="Electronic"><Year>2015</Year><Month>04</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>Spain</Country><MedlineTA>Nutr Hosp</MedlineTA><NlmUniqueID>9100365</NlmUniqueID><ISSNLinking>0212-1611</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001786">Blood Glucose</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004040">Dietary Carbohydrates</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007328">Insulin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nutr Hosp. 2015 Aug 01;32(2):958. doi: 10.3305/nh.2015.32.2.9226.</RefSource><PMID Version="1">26268134</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D001786" MajorTopicYN="N">Blood Glucose</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001939" MajorTopicYN="N">Bread</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D062408" MajorTopicYN="Y">Breakfast</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003924" MajorTopicYN="N">Diabetes Mellitus, Type 2</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004040" MajorTopicYN="Y">Dietary Carbohydrates</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D038321" MajorTopicYN="N">Glycemic Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006943" MajorTopicYN="N">Hyperglycemia</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007328" MajorTopicYN="N">Insulin</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading></MeshHeadingList><OtherAbstract Type="Publisher" Language="spa"><AbstractText>Los carbohidratos (CHO) simples en el riesgo cardiometab&#xf3;lico, conllevan al incremento de la glucemia y los niveles de insulina y, a largo plazo a Diabetes Mellitus tipo 2 (DM2). OBJETIVO: determinar el comportamiento de cifras de glucemia en pacientes DM2 con la ingesta de dos desayunos. METODOLOG&#xcd;A: Se valoraron por antropometr&#xed;a, bioqu&#xed;mica y cl&#xed;nica 14 pacientes con DM2 a quienes se les administr&#xf3; 2 desayunos en tiempos diferentes con 50 g de CHO representados en galleta tipo dulce y pan blanco. RESULTADOS: se evidenci&#xf3; alteraci&#xf3;n en el 92,8% de colesterol de baja Densidad (Ldlc), Colesterol Total (CT) y Colesterol de alta densidad (Hdlc) en el 50% y triacilglicerol (TG) en un 35,7%. El comportamiento de la glucemia para el desayuno con galleta no present&#xf3; diferencia significativa en la cifra preprandial y postprandial a las 2 y 3 horas (p= 0,051 y 0,054 respectivamente) la glucemia de las 2 horas con las 3 horas mostraron significancia (p=0,012). En el desayuno con pan blanco la glucemia preprandial y postprandial a las 2 horas aument&#xf3; (p= 0,006), en tanto, que a las 3 horas, la cifra reportada entre las 2 y 3 horas no presentaron diferencias significativas ( p= 0,114 y 0,051 respectivamente). Al comparar cada una de las glucemias de los desayunos en los periodos preprandial a las 2 y 3 horas no se encontraron diferencias estad&#xed;sticamente significativas (p&amp;gt;0,05). CONCLUSI&#xd3;N: cantidades isocal&#xf3;ricas de carbohidratos de 2 desayunos ingeridos en d&#xed;as diferentes se comportaron de igual manera en las cifras de glucemia. El desayuno con galleta favorecer&#xed;a a la poblaci&#xf3;n diab&#xe9;tica por los ingredientes utilizados en su elaboraci&#xf3;n dada su dislipidemia.</AbstractText><CopyrightInformation>Copyright AULA MEDICA EDICIONES 2014. Published by AULA MEDICA. All rights reserved.</CopyrightInformation></OtherAbstract></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>3</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>3</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>12</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25795941</ArticleId><ArticleId IdType="doi">10.3305/nh.2015.31.4.8304</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">19768247</PMID><DateCompleted><Year>2011</Year><Month>02</Month><Day>02</Day></DateCompleted><DateRevised><Year>2019</Year><Month>09</Month><Day>17</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1677-9487</ISSN><JournalIssue CitedMedium="Internet"><Volume>53</Volume><Issue>5</Issue><PubDate><Year>2009</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Arquivos brasileiros de endocrinologia e metabologia</Title><ISOAbbreviation>Arq Bras Endocrinol Metabol</ISOAbbreviation></Journal><ArticleTitle>[Glycemic index and glycemic load in the prevention and treatment of type 2 diabetes mellitus].</ArticleTitle><Pagination><StartPage>560</StartPage><EndPage>571</EndPage><MedlinePgn>560-71</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">S0004-27302009000500009</ELocationID><Abstract><AbstractText>The tight glycemic control can prevent and/or delay the development of chronic complications of diabetes mellitus (DM). Dietary carbohydrates are the main determinant of postprandial blood glucose and glycemic index (GI) and glycemic load are used to predict blood glucose response to foods. The aim of this paper was to critically review the role of low GI diets in type 2 diabetes mellitus (T2DM) prevention and metabolic control. The risk for development of T2DM with high GI diets ranged from 1.21 to 1.59.The reduction from 12-32 units in the GI of diets decreased 0.39-0.50% in HbA1c values. However, the effects of these diets on lipid profile and body weight in patients with T2DM remain controversial. In conclusion, the current evidence indicates that the inclusion of GI in the dietary planning for patients with T2DM contributes to the improvement of glycemic control.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Silva</LastName><ForeName>Fl&#xe1;via Moraes</ForeName><Initials>FM</Initials><AffiliationInfo><Affiliation>Servi&#xe7;o de Endocrinologia, Hospital de Cl&#xed;nicas de Porto Alegre, Universidade Federal do Rio Grande do Sul (UFRGS), Porto Alegre, RS, Brasil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Steemburgo</LastName><ForeName>Thais</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Azevedo</LastName><ForeName>Mirela J de</ForeName><Initials>MJ</Initials></Author><Author ValidYN="Y"><LastName>Mello</LastName><ForeName>Vanessa D de</ForeName><Initials>VD</Initials></Author></AuthorList><Language>por</Language><PublicationTypeList><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><VernacularTitle>Papel do &#xed;ndice glic&#xea;mico e da carga glic&#xea;mica na preven&#xe7;&#xe3;o e no controle metab&#xf3;lico de pacientes com diabetes melito tipo 2.</VernacularTitle></Article><MedlineJournalInfo><Country>Brazil</Country><MedlineTA>Arq Bras Endocrinol Metabol</MedlineTA><NlmUniqueID>0403437</NlmUniqueID><ISSNLinking>0004-2730</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001786">Blood Glucose</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004040">Dietary Carbohydrates</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007328">Insulin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001786" MajorTopicYN="N">Blood Glucose</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="Y">analysis</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003924" MajorTopicYN="N">Diabetes Mellitus, Type 2</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004040" MajorTopicYN="N">Dietary Carbohydrates</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D038321" MajorTopicYN="Y">Glycemic Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007328" MajorTopicYN="N">Insulin</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2009</Year><Month>3</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2009</Year><Month>4</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>9</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>9</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>2</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19768247</ArticleId><ArticleId IdType="doi">10.1590/s0004-27302009000500009</ArticleId><ArticleId IdType="pii">S0004-27302009000500009</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">16628275</PMID><DateCompleted><Year>2007</Year><Month>05</Month><Day>03</Day></DateCompleted><DateRevised><Year>2022</Year><Month>12</Month><Day>07</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0004-2730</ISSN><JournalIssue CitedMedium="Print"><Volume>50</Volume><Issue>1</Issue><PubDate><Year>2006</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Arquivos brasileiros de endocrinologia e metabologia</Title><ISOAbbreviation>Arq Bras Endocrinol Metabol</ISOAbbreviation></Journal><ArticleTitle>[Contribution of post-breakfast plasma glucose to the glycemic control of type 2 diabetic patients].</ArticleTitle><Pagination><StartPage>53</StartPage><EndPage>59</EndPage><MedlinePgn>53-9</MedlinePgn></Pagination><Abstract><AbstractText Label="UNLABELLED">Epidemiological studies have documented that postprandial hyperglycemia is the main risk factor for cardiovascular diseases. It has been established that glycated hemoglobin (HbA1C) provides an integrated measure of plasma glucose (PG) of the last 2-3 months. However, the relative contribution of fasting PG (FPG) and postprandial PG (PPG) to the HbA1C value is controversial.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To evaluate FPG and PPG contributions to the HbA1C value in patients with type 2 diabetes mellitus (DM2).</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">53 subjects with stable DM2 were studied. They were treated with oral anti-diabetic agents (n = 27) and/or insulin (n = 26). Each subject went to 3 visits at 2-month-intervals. On each visit, FPG, PPG (2 h after breakfast and lunch), and HbA1C were measured and we provided breakfast and lunch according to their meal habits. PG was measured by glucose-oxidase and HbA1C by ion-exchange chromatography. Statistical analysis was performed by correlation coefficients at a &lt; 0.05 P value.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Correlations were stronger between HbA1C and post-breakfast PG (r: 0.66-0.48), mean FPG (r: 0.64-0.41), glucose area under the curve (r: 0.64-0.46), and mean PPG (r: 0.59-0.41).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Measurement of post-breakfast PG showed to be another valuable tool for type 2 diabetic glucose control monitoring.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sartori</LastName><ForeName>Maria Salete</ForeName><Initials>MS</Initials><AffiliationInfo><Affiliation>Departamento de Cl&#xed;nica M&#xe9;dica, Faculdade de Medicina de Botucatu, UNESP, Botucatu, SP.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aragon</LastName><ForeName>Fl&#xe1;vio Ferrari</ForeName><Initials>FF</Initials></Author><Author ValidYN="Y"><LastName>Padovani</LastName><ForeName>Carlos Roberto</ForeName><Initials>CR</Initials></Author><Author ValidYN="Y"><LastName>Pimenta</LastName><ForeName>Walkyria de P</ForeName><Initials>Wde P</Initials></Author></AuthorList><Language>por</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>Contribui&#xe7;&#xe3;o da glicemia p&#xf3;s-desjejum para o controle glic&#xea;mico do paciente com diabetes melito tipo 2.</VernacularTitle><ArticleDate DateType="Electronic"><Year>2006</Year><Month>04</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>Brazil</Country><MedlineTA>Arq Bras Endocrinol Metabol</MedlineTA><NlmUniqueID>0403437</NlmUniqueID><ISSNLinking>0004-2730</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001786">Blood Glucose</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D006442">Glycated Hemoglobin A</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.1.3.4</RegistryNumber><NameOfSubstance UI="D005949">Glucose Oxidase</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Arq Bras Endocrinol Metabol. 2006 Feb;50(1):4-5. doi: 10.1590/s0004-27302006000100002.</RefSource><PMID Version="1">16628269</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D001786" MajorTopicYN="N">Blood Glucose</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002852" MajorTopicYN="N">Chromatography, Ion Exchange</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003924" MajorTopicYN="N">Diabetes Mellitus, Type 2</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005215" MajorTopicYN="N">Fasting</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005949" MajorTopicYN="N">Glucose Oxidase</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000652" MajorTopicYN="N">urine</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006442" MajorTopicYN="N">Glycated Hemoglobin</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006943" MajorTopicYN="N">Hyperglycemia</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019518" MajorTopicYN="Y">Postprandial Period</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011237" MajorTopicYN="N">Predictive Value of Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012680" MajorTopicYN="N">Sensitivity and Specificity</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>4</Month><Day>22</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>5</Month><Day>4</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>4</Month><Day>22</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16628275</ArticleId><ArticleId IdType="doi">10.1590/s0004-27302006000100008</ArticleId><ArticleId IdType="pii">S0004-27302006000100008</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">16106313</PMID><DateCompleted><Year>2006</Year><Month>02</Month><Day>16</Day></DateCompleted><DateRevised><Year>2020</Year><Month>04</Month><Day>13</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0021-7557</ISSN><JournalIssue CitedMedium="Print"><Volume>81</Volume><Issue>4</Issue><PubDate><Year>2005</Year><Season>Jul-Aug</Season></PubDate></JournalIssue><Title>Jornal de pediatria</Title><ISOAbbreviation>J Pediatr (Rio J)</ISOAbbreviation></Journal><ArticleTitle>[Accuracy, utility and complications of continuous glucose monitoring system (CGMS) in pediatric patients with type 1 diabetes].</ArticleTitle><Pagination><StartPage>293</StartPage><EndPage>297</EndPage><MedlinePgn>293-7</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To evaluate the accuracy, utility and complications of continuous glucose monitoring system in children and adolescents with type 1 diabetes.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">This retrospective study assessed 16 type 1 diabetic patients (16.12+/-4.41 years) submitted to continuous glucose monitoring system (Medtronic; Northridge, CA) for 72 hours. The following parameters were analyzed: mean capillary glucose level and mean glucose value measured by the continuous glucose monitoring system; glucose excursions (continuous glucose monitoring system vs. capillary glucose measurement), postprandial hyperglycemia (NR &lt; 140 mg/dl), nocturnal hypoglycemia, complications (trauma, local infection, disconnection) and therapeutic management after continuous glucose monitoring. A1c levels were measured at the beginning and after 3 months of the study.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The mean capillary glucose values were 214.3+/-66.5 mg/dl vs. 207.6+/-54.6 mg/dl by continuous glucose monitoring system, with a significant correlation (p = 0.001). The correlation coefficient and mean absolute error were 0.86+/-0.21 and 12.6% of the median, respectively. The continuous glucose monitoring system was significantly more efficient in detecting glucose excursion than fingerstick capillary blood sampling (p = 0.04; W = 74), and postprandial hyperglycemia was identified in 60% of type 1 diabetic patients with a median value of 157 mg/dl (&lt; 140 mg/dl). Nocturnal hypoglycemia was detected in 46.7% of these patients. The evaluation of A1c levels in eight (50%) patients before continuous glucose monitoring and after 3 months showed a significantly lower level of A1c in this population (8.18+/-1.5 vs. 7.28+/-1.3; p = 0.034). The therapeutic management of type 1 diabetes was changed in 100% of patients. No complications were detected in 93.7% of patients.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The continuous glucose monitoring system showed to be a very safe, well-tolerated and highly accurate method, with a low complication rate. It is a good method to identify glucose excursion and postprandial hyperglycemia, and to improve metabolic changes in therapeutic strategies, with a significant impact on the A1c levels of pediatric diabetic patients. The efficacy of the continuous glucose monitoring system in detecting hypoglycemia is still unclear in the medical literature.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Maia</LastName><ForeName>Frederico F R</ForeName><Initials>FF</Initials><AffiliationInfo><Affiliation>Faculdade de Ci&#xea;ncias M&#xe9;dicas de Minas Gerais (FCMMG), Belo Horizonte, MG, Brazil. fredfrm@hotmail.com</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ara&#xfa;jo</LastName><ForeName>Levimar R</ForeName><Initials>LR</Initials></Author></AuthorList><Language>por</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D023362">Evaluation Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>Acur&#xe1;cia, utilidade e complica&#xe7;&#xf5;es da monitoriza&#xe7;&#xe3;o subcut&#xe2;nea cont&#xed;nua da glicose (CGMS) em pacientes pedi&#xe1;tricos com diabetes tipo 1.</VernacularTitle></Article><MedlineJournalInfo><Country>Brazil</Country><MedlineTA>J Pediatr (Rio J)</MedlineTA><NlmUniqueID>2985188R</NlmUniqueID><ISSNLinking>0021-7557</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001786">Blood Glucose</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007004">Hypoglycemic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007328">Insulin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>J Pediatr (Rio J). 2005 Jul-Aug;81(4):272-3.</RefSource><PMID Version="1">16106309</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001786" MajorTopicYN="N">Blood Glucose</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="Y">analysis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015190" MajorTopicYN="N">Blood Glucose Self-Monitoring</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000295" MajorTopicYN="Y">instrumentation</QualifierName><QualifierName UI="Q000592" MajorTopicYN="N">standards</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016009" MajorTopicYN="N">Chi-Square Distribution</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003922" MajorTopicYN="N">Diabetes Mellitus, Type 1</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006943" MajorTopicYN="N">Hyperglycemia</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007003" MajorTopicYN="N">Hypoglycemia</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007004" MajorTopicYN="N">Hypoglycemic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007328" MajorTopicYN="N">Insulin</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018670" MajorTopicYN="N">Monitoring, Ambulatory</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000295" MajorTopicYN="Y">instrumentation</QualifierName><QualifierName UI="Q000592" MajorTopicYN="N">standards</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018709" MajorTopicYN="N">Statistics, Nonparametric</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2005</Year><Month>8</Month><Day>18</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>2</Month><Day>17</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2005</Year><Month>8</Month><Day>18</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16106313</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>